{"id":"NCT03089944","sponsor":"AbbVie","briefTitle":"A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis","officialTitle":"A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-28","primaryCompletion":"2019-07-31","completion":"2019-11-08","firstPosted":"2017-03-24","resultsPosted":"2020-07-13","lastUpdate":"2020-07-13"},"enrollment":343,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus (HCV)"],"interventions":[{"type":"DRUG","name":"Glecaprevir/Pibrentasvir","otherNames":["ABT-493","ABT-530"]}],"arms":[{"label":"Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks","type":"EXPERIMENTAL"}],"summary":"A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment with glecaprevir/pibrentasvir and to demonstrate the efficacy of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with glecaprevir/pibrentasvir compared to the historical SVR12 rates of 12 weeks of treatment with glecaprevir/pibrentasvir.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Hepatitis C Virus (HCV) Genotype (GT) 1,2,4,5 and 6-infected Participants in the Per Protocol (PP) Population","timeFrame":"12 weeks after last dose of study drug","effectByArm":[{"arm":"Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 Weeks","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":113,"countries":["United States","Bulgaria","Canada","Czechia","France","Greece","Hungary","Ireland","Israel","Italy","Poland","Portugal","Puerto Rico","Romania","Russia","Spain","Taiwan","United Kingdom","Vietnam"]},"refs":{"pmids":["31682879"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":343},"commonTop":["FATIGUE","PRURITUS","HEADACHE","NAUSEA"]}}